Shares of Endonovo Therapeutics (OTCMKTS:ENDV) have been gaining momentum with a jump of 8% in the past week.
Market Reaction
On Tuesday, ENDV stock ended flat at $0.0180 with 10 shares, compared to its average volume of 109K shares. The stock moved within a range of $0.0180 – 0.0180 after opening trade at $0.0200.
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
Developer and distributor of Innovative Medical Devices, Endonovo Therapeutics (OTCMKTS:ENDV), on March 1, 2022,announced appointment of Garry Michael Kann.
Kann will be heading Corporate Development for designing, leading and executing a fresh corporate ‘build up strategy’. The strategy will entail identifying and acquisition of complementary specialty service providers in construction industry.
Kann will manage and oversee creation and ongoing operations of complete corporate development activities. This will include oversight of potential acquisitions, discussions pertaining to structuring of Transactions for Merger and Acquisition staff.
Kann has been founding partner of Firebird Partners. With over three decades of experience in buyouts and takeovers, Kann is a prominent corporate finance professional. He has finished over 60 merger & acquisition transactions exceeding $2 billion in value.
Mr. Kann said that the primary mission for Endonovo will be to locate and acquire high margin specialty trade sub-contractors. He expressed optimism on acquiring firms that would be accretive to the company’s top line revenue as well as bottom line profits.
Alan Collier, Endonovo’s CEO said that Kann has been a leading voice in M&A community. Collier added that he had the chance to work with him both as business and client and has much confidence in the quality of the work.
Key Quote
In explaining his role with Endonovo, Mr. Kann states, “Our primary mission for this initiative is to locate and acquire high margin specialty trade sub-contractors in the construction industry. We look to acquire companies which will be immediately accretive to Endonovo’s top line revenue and bottom line profits to maximize shareholder value.”
Traders Review
ENDV stock is trading below the 20-Day and 50-Day Moving averages of $0.0186 and $0.0187 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0246.
